Relay rises as combo breast cancer therapy cuts disease progression in early study

Relay Therapeutics

09/09/2024 17:06

(Updates)
    ** Shares of drug developer Relay Therapeutics  RLAY.O  rise
57.29% to a six-month high of $9.81
    ** Company says that its experimental breast cancer
treatment  meaningfully extended the time patients lived without
their disease worsening, in an early-stage trial   
    ** The therapy helped 52 patients live for an average of 9.2
months without the disease worsening, after treatment in the
study
     ** Company to start a late-stage trial for the combination
next year, after discussion with regulators
    ** The treatment, RLY-2608, in combination with
AstraZeneca's  AZN.L  Faslodex, was generally well tolerated
across all doses - RLAY
    ** The trial enrolled 118 heavily pre-treated patients with
PI3K mutant, advanced breast cancer
    ** Stock down ~13%, YTD 

 (Reporting by Sneha S K and Sriparna Roy in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))